Announcement and Offering Details
Q32 Bio (NASDAQ: QTTB), a clinical‑stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases, disclosed that it has commenced an underwritten public offering of common stock and, in lieu of common stock to certain investors, pre‑funded warrants. The offering targets gross proceeds of $200 million. Underwriters have been granted a 30‑day option to purchase up to an additional $30 million of shares at the public offering price, less underwriting discounts and commissions.
Use of Proceeds
The company stated that net proceeds from the offering will be allocated to working capital requirements, including expenses related to research, clinical development, and commercialization activities. Specifically, the funds will support the advancement of bempikibart, an anti‑IL‑7Rα antibody, into future clinical trials.
Underwriting Team
Morgan Stanley, Jefferies and Cantor are acting as joint book‑running managers for the transaction. Oppenheimer & Co. is also serving as a book‑running manager, while H.C. Wainwright & Co. is the lead manager.
Share Price Reaction and Clinical Trial Update
Following the announcement, Q32 Bio’s shares fell 6% in after‑hours trading on Monday. This decline followed a dramatic 90% surge in regular‑hour trading after the company released 36‑week topline results from Part B of its SIGNAL‑AA Phase 2a clinical trial, which evaluates bempikibart in patients with severe or very severe alopecia areata.
Contextual Note
The public offering represents a significant capital‑raising step for Q32 Bio as it moves its lead asset, bempikibart, further along the development pipeline while addressing immediate working‑capital needs.